Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novartis Breast Cancer...

    Novartis Breast Cancer Drug Set to Take on Pfizer's Ibrance, Assuming 2018 Launch

    Written by savita thakur thakur Published On 2016-05-19T12:48:02+05:30  |  Updated On 19 May 2016 12:48 PM IST
    Novartis Breast Cancer Drug Set to Take on Pfizers Ibrance, Assuming 2018 Launch

    A clinical trial testing an experimental breast cancer pill from Novartis has been stopped early because of good results, boosting the Swiss company's efforts to build up its oncology business.


    The news puts Novartis on track to compete with a similar blockbuster product from Pfizer that is already on the market.


    Novartis said on Wednesday that testing of LEE011 in combination with letrozole in the late-stage study had been halted early after it met its goal of significantly extending the time patients lived without their disease progressing.


    LEE011, or ribociclib, belongs to the same drug class as Pfizer's Ibrance. The Novartis product now looks set to be second to market in the category, ahead of Eli Lilly's abemaciclib, according to Berenberg Bank analysts.


    UBS analyst Mark Belsey said LEE011 could achieve peak annual sales of $2.5 billion, assuming a 2018 launch.


    Novartis said it would now initiate discussions with regulatory authorities worldwide about seeking approval for LEE011.


    A key question that remains to be answered is the relative efficacy of LEE011 compared to Ibrance. Novartis said full results of its LEE011 study would be presented at an upcoming medical congress.


    The positive results highlight the importance of oncology to Novartis, which on Tuesday announced plans to split its pharmaceuticals division into two business units, with one focused on cancer.

    breast cancerbreast cancer drugMark BelseyNovartisNovartis OncologyPfizer
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok